Log in to search using one of your social media accounts:

 

Monoclonal B-cell lymphocytosis; not the same as B-cell chronic lymphocytic leukaemia.

CONCLUSIONS: The findings of this study indicate that a sizeable fraction of MBL patients are diagnosed inaccurately with CLL, even after the introduction of the MBL diagnosis. FUNDING: The Danish Cancer Society. TRIAL REGISTRATION: not relevant. PMID: 29206098 [PubMed - in process]
Source: Danish Medical Journal - Category: General Medicine Tags: Dan Med J Source Type: research

Related Links:

We describe the clinicopathologic features of 17 patients who had a hematologic malignancy of various types, were treated, and subsequently developed a lymphoproliferative disorder (LPD). There were 10 men and 7 women with a median age of 59 years (range, 36 to 83 y). The primary hematologic neoplasms included: 5 chronic lymphocytic leukemia/small lymphocytic lymphoma, 3 plasma cell myeloma, 2 acute monoblastic leukemia, and 1 case each of mixed-phenotype acute leukemia, chronic myeloid leukemia, splenic marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, T-cell prolymphocytic leukemia, and peripheral...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
AbstractBackgroundEverolimus, an mTOR inhibitor, is active in refractory lymphomas. However, toxicity with flat dosing limits its usage. Speculatively, pharmacokinetically-targeted dosing could improve tolerability. Therefore, we studied serum-trough dosing with rituximab as maintenance after high-dose cyclophosphamide (HDC) consolidation in lymphoma patients.Patients/methodsAfter HDC, everolimus was dosed to serum trough levels (goal 3 –15 ng/mL), with quarterly rituximab infusions for 1 year while maintaining
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
AbstractVenetoclax is licensed to treat relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL). As part of the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (NICE) invited AbbVie, the manufacturer, to submit evidence on the use of venetoclax, within its licensed indication. The Evidence Review Group (ERG), Warwick Evidence, was asked to provide an independent and critical review of the submitted evidence. Evidence came from three single-arm trials in CLL patients with or without 17p deletion [del(17p])/TP53 chromosomal abnormalities. The anticipated licensed indica...
Source: PharmacoEconomics - Category: Health Management Source Type: research
lon J Abstract Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially curative option, this is true particularly the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic hematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellul...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
Abstract High parental age at childbirth has repeatedly been linked to childhood malignancies, while few studies have focused on the offspring's risk of adult cancer. In this population-based case-control study, we identified 32,000 patients with lymphoid neoplasms, diagnosed at ages 0-79 years during the period 1987-2011, and 160,000 matched controls in Sweden. Using prospectively registered data on their first-degree relatives, we evaluated the impact of parental age on the risk of lymphoid neoplasms by subtype. Overall, each 5-year increment in maternal age was associated with a 3% increase in incidence of offs...
Source: Am J Epidemiol - Category: Epidemiology Authors: Tags: Am J Epidemiol Source Type: research
Publication date: 17 October 2017 Source:Cell Reports, Volume 21, Issue 3 Author(s): Russell J.H. Ryan, Jelena Petrovic, Dylan M. Rausch, Yeqiao Zhou, Caleb A. Lareau, Michael J. Kluk, Amanda L. Christie, Winston Y. Lee, Daniel R. Tarjan, Bingqian Guo, Laura K.H. Donohue, Shawn M. Gillespie, Valentina Nardi, Ephraim P. Hochberg, Stephen C. Blacklow, David M. Weinstock, Robert B. Faryabi, Bradley E. Bernstein, Jon C. Aster, Warren S. Pear Gain-of-function Notch mutations are recurrent in mature small B cell lymphomas such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), but the Notch target genes that ...
Source: Cell Reports - Category: Cytology Source Type: research
Members of the B-cell lymphoma 2 (BCL-2) gene family are attractive targets for cancer therapy as they play a key role in promoting cell survival, a long-since established hallmark of cancer. Clinical utility for selective inhibition of specific anti-apoptotic Bcl-2 family proteins has recently been realized with the Food and Drug Administration (FDA) approval of venetoclax (formerly ABT-199/GDC-0199) in relapsed chronic lymphocytic leukemia (CLL) with 17p deletion. Despite the impressive monotherapy activity in CLL, such responses have rarely been observed in other B-cell malignancies, and preclinical data suggest that co...
Source: Biochemical Journal - Category: Biochemistry Authors: Tags: Review Articles Source Type: research
Abstract Members of the B-cell lymphoma 2 (BCL-2) gene family are attractive targets for cancer therapy as they play a key role in promoting cell survival, a long-since established hallmark of cancer. Clinical utility for selective inhibition of specific anti-apoptotic Bcl-2 family proteins has recently been realized with the Food and Drug Administration (FDA) approval of venetoclax (formerly ABT-199/GDC-0199) in relapsed chronic lymphocytic leukemia (CLL) with 17p deletion. Despite the impressive monotherapy activity in CLL, such responses have rarely been observed in other B-cell malignancies, and preclinical da...
Source: The Biochemical Journal - Category: Biochemistry Authors: Tags: Biochem J Source Type: research
Abstract Chronic lymphocytic leukaemia (CLL) is a non-Hodgkin lymphoma commonly occurring in older adults. Many people with CLL can go for years without requiring treatment. However, they have an increased risk of secondary cancers, specifically melanoma and non-melanoma skin cancers. Furthermore, these secondary cancers are frequently more aggressive in this cohort of patients. Health professionals working in haematology, dermatology and general practice have an opportunity to educate patients about risk factors and measures to aid prevention. Modern technology may assist patients and professionals in the early d...
Source: British Journal of Nursing - Category: Nursing Authors: Tags: Br J Nurs Source Type: research
Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Micro-Abstract Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. To determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Denmark Health | General Medicine | Leukemia | Lymphoma | Study